Evidence map›Paper›PMID 32376564›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2020

[Overexpression of leukemia inhibitory factor enhances chemotherapy tolerance of endometrial cancer cells

Xiaohong Ruan, Meigong Zhong, Wanmin Liu, Qiongru Liu, Wenjie Lu, Yan Zheng, Xin Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaohong RuanDepartment of Gynecology, Jiangmen Central Hospital, Jiangmen 529030, China.
Meigong ZhongDepartment of Pharmacy, Jiangmen Maternity and Child Health Care Hospital, Jiangmen 529000, China.
Wanmin LiuDepartment of Gynecology, Jiangmen Central Hospital, Jiangmen 529030, China.
Qiongru LiuDepartment of Pathology, Jiangmen Central Hospital, Jiangmen 529030, China.
Wenjie LuCentral Laboratory, Jiangmen Central Hospital, Jiangmen 529030, China.
Yan ZhengResearch and Development Center for Molecular Diagnosis Engineering Technology of Human Papillomavirus (HPV) Related Diseases of Guangdong Province, Chaozhou 521021, China.
Xin ZhangDepartment of Pathology, Jiangmen Central Hospital, Jiangmen 529030, China.
Jiangmen Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the effect of overexpression of leukemia inhibitory factor (LIF) on cisplatin and paclitaxel resistance of endometrial cancer cells

methodsEndometrial cancer cell lines HEC-1B and RL95-2 were infected with a recombinant lentivirus to overexpress LIF, and the changes in LIF expression was verified using RT-qPCR and ELISA. The viability of the LIF-overexpressing cells was assessed using CCK-8 assay, and the cell apoptosis and changes in mitochondrial membrane potential in response to cisplatin or paclitaxel treatment were analyzed with annexin V-FITC/PI staining and JC-1 assay, respectively. The effect of LIF overexpression on the expressions of Bcl-2 family proteins and STAT3 pathway was evaluated using Western blotting; dual-luciferase reporter gene assay was employed to detect the transcriptional activity of STAT3. The effect of STAT3 silencing on apoptosis of the LIF-overexpressing cells induced by cisplatin or paclitaxel was investigated.

resultsThe cell lines infected with the recombinant lentivirus showed significantly increased mRNA and protein levels of LIF (

conclusionss Overexpression of LIF can enhance cisplatin and paclitaxel resistance to endometrial cancer cells

Indexed as

Drug Resistance, NeoplasmSignal TransductionAntineoplastic AgentsApoptosisbcl-X ProteinCell Line, TumorCisplatinEndometrial NeoplasmsFemaleHumansLeukemia Inhibitory FactorPaclitaxelProto-Oncogene Proteins c-bcl-2STAT3 Transcription FactorAntineoplastic AgentsBCL2L1 protein, humanBCL2 protein, humanbcl-X ProteinCisplatinLeukemia Inhibitory FactorLIF protein, humanPaclitaxelProto-Oncogene Proteins c-bcl-2STAT3 protein, humanSTAT3 Transcription Factorcisplatinendometrial carcinomaleukemia inhibitory factorpaclitaxelSTAT3 signal pathway

Identifiers

PMID32376564
PMCPMC7040748
OpenAlexW3026181747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.